Core Viewpoint - Propanc Biopharma, Inc. is advancing its lead proenzyme therapy, PRP, as a novel treatment for chronic diseases, particularly targeting solid tumors with high unmet needs like pancreatic cancer [1][5]. Company Overview - Propanc Biopharma, Inc. focuses on developing innovative treatments aimed at preventing cancer recurrence and metastasis by targeting cancer stem cells through proenzyme activation [10]. - The company has received FDA Orphan Drug Designation for PRP in pancreatic cancer, highlighting its potential in a critical treatment gap [5]. Product Details - PRP is an intravenous formulation combining two pancreatic proenzymes, trypsinogen and chymotrypsinogen, designed to inhibit tumor growth and enhance chemosensitivity, showing over 85% tumor growth inhibition in preclinical studies [2][3]. - The therapy aims to address the root causes of cancer proliferation and metastasis, offering a potentially less toxic alternative to existing therapies [3]. Market Opportunity - The global pancreatic cancer treatment market was valued at approximately $3.25 billion in 2025 and is projected to reach $3.70 billion in 2026, with significant growth expected to $10.25 billion by 2034, reflecting a CAGR of 13.62% [6]. - Solid tumors, including pancreatic, ovarian, and colorectal cancers, account for about 80% of all cancers, representing a substantial commercial opportunity for Propanc [7]. Clinical Development - Propanc is preparing for a Phase 1b First-In-Human study in 2026, targeting approximately 30-40 patients with advanced solid tumors, which will inform subsequent Phase 2 studies [8]. - The company is enhancing its intellectual property portfolio with recent provisional patent filings to protect its formulations and therapeutic applications [8]. Strategic Vision - The CEO of Propanc expressed optimism about PRP's potential to transform cancer care by targeting the mechanisms of metastasis, aiming to provide hope to patients with limited treatment options [9].